Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response

BACKGROUND: The absence of the putative DNA/RNA helicase Schlafen11 (SLFN11) is thought to cause resistance to DNA-damaging agents (DDAs) and PARP inhibitors. METHODS: We developed and validated a clinically applicable SLFN11 immunohistochemistry assay and retrospectively correlated SLFN11 tumour le...

Descripción completa

Detalles Bibliográficos
Autores principales: Willis, Sophie E., Winkler, Claudia, Roudier, Martine P., Baird, Tarrion, Marco-Casanova, Paola, Jones, Emma V., Rowe, Philip, Rodriguez-Canales, Jaime, Angell, Helen K., Ng, Felicia S. L., Waring, Paul M., Hodgson, Darren, Ledermann, Jonathan A., Weberpals, Johanne I., Dean, Emma, Harrington, Elizabeth A., Barrett, J. Carl, Pierce, Andrew J., Leo, Elisabetta, Jones, Gemma N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651811/
https://www.ncbi.nlm.nih.gov/pubmed/34663950
http://dx.doi.org/10.1038/s41416-021-01560-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651811/
https://www.ncbi.nlm.nih.gov/pubmed/34663950
http://dx.doi.org/10.1038/s41416-021-01560-1

Ejemplares similares